At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 821 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Everolimus for Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma. Completed, enrolled 821 participants across 168 sites in 24 countries.
Detailed Summary
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Norway, Poland, Romania, Russia, Spain, Sweden, United Kingdom, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartOct 2012
Primary CompletionMay 2015
Study CompletionJul 2021
TodayJul 2026
First PostedAug 20, 2012
Enrollment StartOct 9, 2012
Primary CompletionMay 6, 2015
Study CompletionJul 19, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.9 years ago
Interventions
Nivolumabbiological
Everolimusdrug